Preformulation Characterization and Stability Assessments of Secretory IgA Monoclonal Antibodies as Potential Candidates for Passive Immunization by Oral Administration
Hu, Yue ; Kumru, Ozan S. ; Xiong, Jian ; Antunez, Lorena R. ; Hickey, John ; Wang, Yang ; Cavacini, Lisa A ; Klempner, Mark S. ; Joshi, Sangeeta B. ; Volkin, David B.
Citations
Student Authors
Faculty Advisor
Academic Program
UMass Chan Affiliations
Document Type
Publication Date
Keywords
enterotoxigenic Escherichia coli
formulation
immunization
immunoglobulin G
oral delivery
physicochemical characterization
stability
Amino Acids, Peptides, and Proteins
Bacterial Infections and Mycoses
Complex Mixtures
Enzymes and Coenzymes
Immunoprophylaxis and Therapy
Medicinal Chemistry and Pharmaceutics
Pharmacy and Pharmaceutical Sciences
Therapeutics
Subject Area
Embargo Expiration Date
Link to Full Text
Abstract
Enterotoxigenic Escherichia coli (ETEC) is a major cause of diarrheal disease in children in developing countries, and there are no licensed vaccines to protect against ETEC. Passive immunization by oral delivery of ETEC-specific secretory IgAs (sIgAs) could potentially provide an alternative approach for protection in targeted populations. In this study, a series of physiochemical techniques and an in vitro gastric digestion model were used to characterize and compare key structural attributes and stability profiles of three anti-heat labile enterotoxin monoclonal antibodies (sIgA1, sIgA2 and IgG1 produced in CHO cells). The mAbs were evaluated in terms of primary structure, N-linked glycan profiles, size and aggregate content, relative apparent solubility, conformational stability, and in vitro antigen binding. Compared to IgG1 mAb, sIgA1 and sIgA2 mAbs showed increased sample heterogeneity, especially in terms of N-glycan composition and the presence of higher molecular weight species. The sIgA mAbs showed overall better physical stability and were more resistant to loss of antigen binding activity during incubation at low pH, 37 degrees C with pepsin. These results are discussed in terms of future challenges to design stable, low-cost formulations of sIgA mAbs as an oral supplement for passive immunization to protect against enteric diseases in the developing world.
Source
J Pharm Sci. 2019 Jul 29. pii: S0022-3549(19)30453-8. doi: 10.1016/j.xphs.2019.07.018. [Epub ahead of print] Link to article on publisher's site